Literature DB >> 16049125

Localization and mRNA expression of CYP3A and P-glycoprotein in human duodenum as a function of age.

May Fakhoury1, Catherine Litalien, Yves Medard, Hélène Cavé, Nadia Ezzahir, Michel Peuchmaur, Evelyne Jacqz-Aigrain.   

Abstract

Cytochromes P450 3A (CYP3A) and P-glycoprotein (P-gp) are mainly located in enterocytes and hepatocytes. The CYP3A/P-gp system contributes to the first-pass metabolism of many drugs, resulting in a limited bioavailability. During the neonatal period, a shift between CYP3A7, the fetal form, and CYP3A4 occurs in the liver, but data on the expression of the CYP3A/P-gp complex in the intestine are very limited. A total of 59 normal duodenal biopsies from white children aged 1 month to 17 years were studied. Localization of the proteins by immunohistochemistry analysis was performed using a polyclonal antibody, Nuage anti-CYP3A, and a monoclonal antibody, C494 anti-P-gp. The mRNA quantification was performed using highly specific real-time reverse transcription-polymerase chain reaction. Villin mRNA quantification was used for normalization. CYP3A protein was detected in all enterocytes in the samples from patients over 6 months of age, whereas it was not in younger samples. P-gp protein was expressed at the apical and upper lateral surfaces of the enterocytes. CYP3A isoforms and P-gp mRNA levels were highly variable. CYP3A4 and CYP3A5 mRNA levels were high during the first year of life and decreased with age, whereas CYP3A7 was detected at a low level in 64% of samples, whatever the age. P-gp mRNA expression level was also highly variable. Our results showed that neonates and infants had a significant expression of CYP3A and P-gp mRNA in the intestine, suggesting a different maturation profile of CYP3A and P-gp with age in the liver and the intestine.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16049125     DOI: 10.1124/dmd.105.005611

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  39 in total

1.  Ontogenic expression of human carboxylesterase-2 and cytochrome P450 3A4 in liver and duodenum: postnatal surge and organ-dependent regulation.

Authors:  Yi-Tzai Chen; Lynnie Trzoss; Dongfang Yang; Bingfang Yan
Journal:  Toxicology       Date:  2015-02-24       Impact factor: 4.221

2.  Prediction of Voriconazole Non-linear Pharmacokinetics Using a Paediatric Physiologically Based Pharmacokinetic Modelling Approach.

Authors:  Trevor N Johnson; Farzaneh Salem; Masoud Jamei; Amin Rostami-Hodjegan
Journal:  Clin Pharmacokinet       Date:  2015-05       Impact factor: 6.447

3.  Response to: "Prediction of Voriconazole Non-Linear Pharmacokinetics Using a Paediatric Physiologically Based Pharmacokinetic Modelling Approach".

Authors:  Nicole R Zane; Dhiren R Thakker
Journal:  Clin Pharmacokinet       Date:  2015-05       Impact factor: 6.447

Review 4.  Neonatal cytochrome P450 CYP3A7: A comprehensive review of its role in development, disease, and xenobiotic metabolism.

Authors:  Haixing Li; Jed N Lampe
Journal:  Arch Biochem Biophys       Date:  2019-08-22       Impact factor: 4.013

Review 5.  Paediatric pharmacokinetics: key considerations.

Authors:  Hannah Katharine Batchelor; John Francis Marriott
Journal:  Br J Clin Pharmacol       Date:  2015-03       Impact factor: 4.335

6.  A Preterm Physiologically Based Pharmacokinetic Model. Part I: Physiological Parameters and Model Building.

Authors:  Khaled Abduljalil; Xian Pan; Amita Pansari; Masoud Jamei; Trevor N Johnson
Journal:  Clin Pharmacokinet       Date:  2020-04       Impact factor: 6.447

7.  Mind the Gaps: Ontogeny of Human Brain P-gp and Its Impact on Drug Toxicity.

Authors:  Jean-Marie Nicolas; Elizabeth C M de Lange
Journal:  AAPS J       Date:  2019-05-28       Impact factor: 4.009

Review 8.  Summary of the National Institute of Child Health and Human Development-best pharmaceuticals for Children Act Pediatric Formulation Initiatives Workshop-Pediatric Biopharmaceutics Classification System Working Group.

Authors:  Susan M Abdel-Rahman; Gordon L Amidon; Ajay Kaul; Viera Lukacova; Alexander A Vinks; Gregory T Knipp
Journal:  Clin Ther       Date:  2012-11       Impact factor: 3.393

9.  Pharmacokinetic interaction between oral lovastatin and verapamil in healthy subjects: role of P-glycoprotein inhibition by lovastatin.

Authors:  Dong-Hyun Choi; Joong-Hwa Chung; Jun-Shik Choi
Journal:  Eur J Clin Pharmacol       Date:  2009-12-12       Impact factor: 2.953

10.  Developmental pharmacogenetics of CYP2C19 in neonates and young infants: omeprazole as a probe drug.

Authors:  Wei Zhao; Stéphanie Leroux; Valérie Biran; Evelyne Jacqz-Aigrain
Journal:  Br J Clin Pharmacol       Date:  2018-03-09       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.